/* */ PELVIPHARM - Testosterone-supplemented SHR as a model of BPH / male LUTS
Receive our news

 

Testosterone-supplemented SHR as a model of BPH / male LUTS

Model advantages

The testosterone-supplemented SHR combines erectile dysfunction, prostate enlargement and urodynamic impairment characteristic of LUTS and allows thus the assessment of erectile function in parallel to bladder function and prostate size.
This model helps to assess the sexual side-effect profile of new therapeutic strategies for BPH while evaluating their efficacy on LUTS and prostate enlargement.

Pathophysiological features

Erectile dysfunction:

  • Dramatic impairment of erectile responses to electrical stimulation of the cavernous nerve after 3 weeks of testosterone supplementation in anesthetized SHR (figure 1).  
Figure 1: In vivo evidence of erectile dysfunction in testosterone-supplemented SHR. (Pelvipharm, internal data)

Bladder dysfunction

  • Exhibits abnormal bladder function: decreased ICI, voided volume and bladder capacity, and increased urinary frequency and amplitude of non voiding contractions characteristic of detrusor overactivity.

Figure 2: Urodynamic parameters in WKY and SHR supplemented with testosterone (SHR-testo) measured in conscious rats after a 3-week testosterone supplementation period (Pelvipharm internal data). Prostate enlargement

The testosterone-supplemented SHR exhibits several common characteristics with the human pathology:

  • Prostatic enlargement (figure 3)
  • Combined increase in both prostate cell size (protein content) and number (DNA content)

    Figure 3: Evaluation of prostate enlargement induced by daily s.c. testosterone injections during 3 weeks in SHR (Pelvipharm, internal data)


    Summarized methodology

    Testosterone is administered subcutaneously daily in SHR.
Related Pelvipharm bibliography
Oudot A., et al.
J Urol (2011) : 185, 4, Suppl 1, p.e631

Oudot A., et al.
J Sex Med (2010) : 7(s6)
SITEMAP
TEL +331 704 293 39
FAX + 331 704 295 10
LEGAL